Randomized Phase IIa Clinical Study of an Anti-α_vβ₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

Am J Respir Crit Care Med. 2022 Nov 1;206(9):1166-1168. doi: 10.1164/rccm.202205-0868LE.

Authors

Affiliations

¹ Center for Interstitial Lung Diseases University of Washington Medical Center Seattle, Washington.
² Biogen, Inc. Cambridge, Massachusetts.
³ Department of Pneumology Medical School of Hannover Hannover, Germany.
⁴ Division of Pulmonary, Allergy, and Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Antigens, Neoplasm
Humans
Idiopathic Pulmonary Fibrosis*
Transforming Growth Factor beta

Substances

Antibodies, Monoclonal
Antigens, Neoplasm
Transforming Growth Factor beta